Given that media reporting in May 2023 had identified the availability of such products, this finding can be seen as potential evidence of the effectiveness of letters sent by the FDA in late April and October 2023 to the National Association of Boards of Pharmacy and the Federation of State Medical Boards indicating that compounding these salt forms would not meet the requirements of the FD&C Act (U.S
doi: 10.1186/s40814-023-01235-z Summary Keywords depressive disorder, gut microbiota, gut-brain axis (GBA), dysbiosis, metabolites, probiotics, prebiotics, FMT Citation Luqman A, He M, Hassan A, Ullah M, Zhang L, Rashid Khan M, Din AU, Ullah K, Wang W and Wang G (2024) Mood and microbes: a comprehensive review of intestinal microbiotas impact on depression
EXPECTED EFFECTS BOOK NOW 12 Weeks: Noticeable reduction in inflammation and pain
The trials were double-blind, meaning neither the patients nor the researchers knew who received which treatment
